Raymond James upgrades Kymera Therapeutics to moderate buy
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Raymond James Financial upgraded Kymera Therapeutics (NASDAQ:KYMR) to a "moderate buy" rating, with an analyst price target of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context